GLP1R and diabetes mellitus: In view of the treatment heterogeneity observed here for GLP-1 receptor agonists in individuals with poor glycaemic control, one would certainly like to see a trial that compares GLP-1 receptor agonists with a placebo in a repeated-crossover design, preferably also assessing other outcomes such as body weight or diabetes-related complications.